Global Printing Equipment Market: Industry Analysis & Outlook (2017-2021) – Augmented Demand for Digital Print – Research and Markets

DUBLIN–(BUSINESS WIRE)–The „Global Printing Equipment Market: Industry Analysis & Outlook (2017-2021)” report has been added to Research and Markets’ offering.

Printing in today’s world has allowed people to share large amount of information quickly. The invention of the printing press is considered to be very significant, which drastically changed evolving economies. The printed material from printing presses is put to use by its end users in various categories, broadly classified under commercial, publishing, advertising, packaging, and security.

Offset printing is considered to be a key process, which is further classified under two segments i.e. sheetfed and web offset, digital and flexo. Amongst these, the most cost-effective process is offset, but digital printing is gaining the maximum momentum. Large online retailers are also heading towards digital printing as per their convenience.

The global printing equipment market is mature in the developed nations, but holds huge amount of opportunities in the developing regions especially in countries like India, China and Indonesia. The printing market has a great scope of innovation. The growth factors of the market include digital print, robust growth in Asia, increase in packaging printing demand, and growing education levels.

The global market has high opportunities to grow via technological push along with other major trends like rising productivity, consolidation among printers, and growing scope of 3D printing. However, the market growth will be hindered by high cost structure, migration to digital media and a sensitive pricing environment.

The report offers an in-depth analysis of the global printing market along with printing equipment market. The top notch players in the market exhibit a very close competition. The report profiles Koenig & Bauer, Heidelberger Druckmaschinen AG, KOMORI Corporation, and Ryobi Group.

Companies Mentioned

  • Heidelberger Druckmaschinen AG
  • KOMORI Corporation
  • Koenig & Bauer
  • Ryobi Group

Key Topics Covered:

1. Market Overview

2. Global Market Analysis

3. Global Printing Equipment Market

4. Market Dynamics

5. Competitive Landscape

6. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/38bmct/global_printing

Global Printing Equipment Market: Industry Analysis & Outlook (2017-2021) – Augmented Demand for Digital Print – Research and Markets

DUBLIN–(BUSINESS WIRE)–The „Global Printing Equipment Market: Industry Analysis & Outlook (2017-2021)” report has been added to Research and Markets’ offering.

Printing in today’s world has allowed people to share large amount of information quickly. The invention of the printing press is considered to be very significant, which drastically changed evolving economies. The printed material from printing presses is put to use by its end users in various categories, broadly classified under commercial, publishing, advertising, packaging, and security.

Offset printing is considered to be a key process, which is further classified under two segments i.e. sheetfed and web offset, digital and flexo. Amongst these, the most cost-effective process is offset, but digital printing is gaining the maximum momentum. Large online retailers are also heading towards digital printing as per their convenience.

The global printing equipment market is mature in the developed nations, but holds huge amount of opportunities in the developing regions especially in countries like India, China and Indonesia. The printing market has a great scope of innovation. The growth factors of the market include digital print, robust growth in Asia, increase in packaging printing demand, and growing education levels.

The global market has high opportunities to grow via technological push along with other major trends like rising productivity, consolidation among printers, and growing scope of 3D printing. However, the market growth will be hindered by high cost structure, migration to digital media and a sensitive pricing environment.

The report offers an in-depth analysis of the global printing market along with printing equipment market. The top notch players in the market exhibit a very close competition. The report profiles Koenig & Bauer, Heidelberger Druckmaschinen AG, KOMORI Corporation, and Ryobi Group.

Companies Mentioned

  • Heidelberger Druckmaschinen AG
  • KOMORI Corporation
  • Koenig & Bauer
  • Ryobi Group

Key Topics Covered:

1. Market Overview

2. Global Market Analysis

3. Global Printing Equipment Market

4. Market Dynamics

5. Competitive Landscape

6. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/38bmct/global_printing

Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021) – Upcoming Novel Drugs to Drive Growth of Hereditary Angioedema Market – Research and Markets

DUBLIN–(BUSINESS WIRE)–The „Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021)” report has been added to Research and Markets’ offering.

Hereditary Angioedema (HAE) is a rare hereditary disease caused by a genetic deficiency in a gene known as C1 inhibitor (C1-INH). It is characterized by attacks of edema (swelling). These are unpredictable and can affect various areas of the body including the stomach, hands, feet, arms, legs, genitals, throat, and face. Depending on the severity of the disease, some people can have many attacks each month, while others go months without an attack.

The global hereditary angioedema market is set to experience favourable growth driven by factors such as increasing diagnosis of hereditary angioedema & rising health care expenditure. Further, the scope of growth for this market will be broadened by increasing uptake of prophylaxis therapy and global economic development. The major trends that can be observed in this market include introduction of novel drugs, increasing awareness for HAE and oral medication for HAE attacks.

The report „Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021)” analyses the development of this market, with focus on the U.S. and European markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players Shire Plc., CSL Limited, Pharming Group N.V. & BioCryst Pharmaceuticals Inc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global Hereditary Angioedema market along with the study of the regional markets.

Companies Mentioned

  • BioCryst Pharmaceuticals Inc.
  • CSL Limited
  • Pharming Group N.V.
  • Shire Plc.

Key Topics Covered:

1. Overview

2. Global Hereditary Angioedema Market

3. Regional Market

4. Market Dynamics

5. Competition

6. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/ntvggc/global_hereditary

North America Insulin Pump Market – Likely to Reach More Than US$ 4.2 Billion by the Year End of 2022 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The „North America Insulin Pump Market Prospect, Share, Development, Growth and Demand Forecast to 2022” report has been added to Research and Markets’ offering.

The North American Insulin Pump Market is likely to reach more than US$ 4.2 Billion by the year end of 2022.

Long-term Growth Projection:

  • Number of diabetes population in United States will increase to more than 33 Million by the year end of 2022
  • In 2016, there were more than 5,00,000 insulin pump users in United States
  • Canada Insulin Pump market generated more than US$ 160 Million in 2016
  • The US is the major market share holder for the North America Insulin Pump Market

Increasing number of diabetic patients, growing awareness towards diabetes, improved glucose control and flexible, lifestyle-compatible treatment options and technological advancement in insulin pump devices are the key factors driving the growth of the North America Insulin Pump Market. However, high cost of the insulin pump devices is expected to hamper growth of the market during forecast period.

The report concludes with the profiles of major players in the Insulin Pump Market such as Insulet Corporation, Medtronic, Roche, Animas Corporation, Tandem Diabetes Care, Microport and Sooil Development. The major market players are evaluated on various parameters such as company overview, product outlook, latest development and trends and sales analysis of the Insulin Pump and Diabetes Market from 2011 to 2022.

Companies Mentioned

  • Animas Corporation
  • Insulet Corporation
  • Medtronic
  • Microport
  • Roche
  • Sooil Development
  • Tandem Diabetes Care

Key Topics Covered:

1. Executive Summary

2. North America Diabetes Population (2011 – 2022): An Analysis

3. North America Insulin Pump Market Prospect & Growth (2011 – 2022)

4. North America Insulin Pump Market Share – By Countries (2011 – 2022)

5. North America Insulin Pump Market Analysis – By Countries (2011- 2022)

6. Key Drivers and Inhibitors of the North America Insulin Pump Market

7. North America Insulin Pump Market: Reimbursement & Regulation System

8. North America Insulin Pump Market – Major Deal Types

9. Insulin Pump Market Clinical Trail Insight by Phase, Company & Country

10. Key Companies Analysis 

For more information about this report visit https://www.researchandmarkets.com/research/qnp7d9/north_america

ALine, Inc. and Triple Ring Technologies Form a Strategic Partnership

RANCHO DOMINGUEZ, Calif.–(BUSINESS WIRE)–ALine and Triple Ring Technologies (TRT) announce a strategic partnership to support clients developing diagnostic products in which a microfluidic consumable is supported with instrument automation. Triple Ring excels at collaborating across disciplines, and combines deep domain expertise with enabling technologies to deliver product solutions for its clients. ALine brings both scientific and engineering expertise to the design and development of microfluidics, offering integrated fluidic solutions that easily scale for volume production. By working together, both ALine and TRT can better support the complex systems integration issues required to develop robust products for the ever-growing diagnostics market.

TRT is a technology-driven product development company that provides outsourced science and engineering services for clients large and small. Dr. Leanna Levine, President of ALine, commented, “We are pleased to be working with a world-class organization that has a track record of successfully nurturing start-ups as well as adding value to the product pipelines of large medical device and life sciences companies. We enjoy the professionalism of the Triple Ring team, and the opportunity to be engaged with exciting and innovative product opportunities.”

ALine’s unique blend of engineering know-how, scientific acumen, and rapid prototyping enables a development program to move quickly through the design build test cycle, optimizing the device, assay, and instrument interface together. “We really like ALine’s approach to microfluidic development, and the many ‘off the shelf’ fluidic solutions that we can integrate into our clients’ product design. Their manufacturing capability will allow us to scale quickly to meet our clients’ demanding ramp schedules,” commented Dr. Joe Heanue, CEO of Triple Ring Technologies.

About ALine – Located in Los Angeles County, ALine specializes in the design and development of microfluidic consumables with applications in diagnostics and life sciences. The company offers scientific and engineering expertise, solving tough integration requirements for microfluidics-based products. We support clients from early development through scale up and product launch with our strategic manufacturing partners. ISO9001:2008 certified.

About Triple Ring Technologies – Located in Silicon Valley, Triple Ring Technologies is a leading research and development firm that, together with our clients, solves critical, often complex technical challenges. We work across the development process in medical devices, in vitro diagnostics, life science tools, and imaging systems.

Peer-Review-Zeitschriften haben mehr als 200 Forschungsartikel über den EnvisionTEC 3D-Bioplotter veröffentlicht

DEARBORN, Mich.–(BUSINESS WIRE)–Der EnvisionTEC 3D-Bioplotter® hat mit mehr als 200 wissenschaftlichen, technischen und medizinischen Forschungsarbeiten, die jetzt in Fachzeitschriften veröffentlicht werden, seine Position als der am meisten recherchierte Bioprinter in der Welt weiter gesichert.

EnvisionTEC, ein weltweit führender Hersteller von Desktop- und Vollproduktions-3D-Druckern und -Materialien, bietet drei Versionen des 3D-Bioplotters an – eine Starter-, Entwickler- und Hersteller-Serie –, um die Nachfrage nach verschiedenen Funktionen zu erfüllen.

Im Jahr 2016 startete EnvisionTEC eine Online-Datenbank, um die wachsende Menge an Forschung mit seinem Bioprinter an Universitäten, Hochschulen, Krankenhäusern und Unternehmen weltweit zu verfolgen.

„Die Vielfalt und Tiefe dieser Papiere demonstrieren die fortschrittliche Forschung, die unsere Kunden mit unserer Premium-Technologie ausführen können“, sagte Carlos Carvalho, der die Entwicklung der vierten Generation des 3D-Bioplotters leitete und seit seinem Anfangsstadium an der Arbeit am Bioprinter an der Universität Freiburg beteiligt war.

Eine Vielzahl von Themen werden in der 3D-Druckforschungsdatenbank (abrufbar unter www.envisiontec.com/bioprinter) behandelt, z. B.:

  • Regeneration von Knochen, Knorpeln, Weichgewebe, Nerven, Sehnen und Zähnen
  • Organ-Druck, einschließlich eines bioprosthetischen Maus-Eierstocks, der erfolgreich in-vivo implantiert wurde, was zu einer Lebendgeburt führte
  • Direkter Zelldruck
  • Trachea-Rekonstruktion
  • Rückenmarkverletzungen
  • Arzneimittelfreisetzung, wie Gentherapie und Behandlung von Epilepsie oder Tuberkulose
  • Partikel-basierte Tinten, die Mischungen aus Polymeren, Keramiken und Metallen sind

Eine der jüngsten Ergänzungen der Forschungsdatenbank erforscht die Reparatur von Trommelfell-Perforationen (TMPs) mit maßgeschneiderten Bioprint-Ohrtransplantaten. Ein weiterer Artikel untersucht, wie man Herz-Patches aus 3D-gedruckten Alginat-Hydrogelen für Herzinfarkt- oder Myokardinfarkt-Reparatur nach der Implantation röntgt oder visualisiert.

Obwohl ein Großteil der Forschung mit dem 3D-Bioplotter in-vitro oder außerhalb eines lebenden Organismus durchgeführt wurde, gibt es eine wachsende Anzahl von In-vivo-Arbeiten bei kleinen und großen Tieren. Da die 3D-Bioprintforschung weiter reift, erwartet EnvisionTEC, dass die Arbeit in der kommenden Zeit an lebenden Menschen vorgenommen wird.

Der 3D-Bioplotter wird auch verwendet, um Forschung außerhalb der traditionellen Medizin, mit Nahrung, außerirdischen Baustoffen usw. durchzuführen. Zum Beispiel wurden 3D-gedruckte elektrisch leitfähige Materialien mit Sensoren und Softrobotern erforscht. Die Forscher drucken auch Partikel-basierte Tinten, die Mischungen aus Polymeren, Keramiken und Metallen sein können, um Objekte zum Backen oder Sintern in einer Nachbearbeitungsphase zu bauen, um vollständig dichte Metallteile zu erzeugen. Diese Art von Prozess könnte schließlich verwendet werden, um eine Vielzahl von Objekten besser zu machen, einschließlich Batterien und Brennstoffzellen.

Die erste Generation des 3D-Bioplotters, die gemeinsam mit der Universität Freiburg entwickelt wurde, befindet sich nun in der vierten Generation. Mit mehr als 15 Jahren Hardware- und Softwareentwicklung ist der 3D-Bioplotter eine einfach zu bedienende modulare Maschine mit erweiterten Funktionen und Fähigkeiten. Die robuste Maschine verarbeitet Open-Source-Biomaterialien mit Luft- oder mechanischem Druck zu einer Vielzahl von Spritzen, die Gerüste herstellen können, um Gewebe, Organe und mehr zu erzeugen. Das 3D-Bioplotter-System bietet leicht konfigurierbare, komplexe Innenmuster-Designs und wurde für den Einsatz in einem sterilen Biosicherheitskabinett entwickelt, das Standards für klinische Studien erfüllt.

Über EnvisionTEC

EnvisionTEC ist ein weltweit führender Anbieter von 3D-Druck-Lösungen für professionelle Anwendungen. Das 2002 gegründete Unternehmen EnvisionTEC mit seiner bahnbrechenden kommerziellen DLP-Drucktechnik vertreibt mittlerweile über 40 Druckerkonfigurationen auf der Grundlage von sechs unterschiedlichen Technologien, mit denen Gegenstände ausgehend von digitalen Dateien angefertigt werden. Die hochwertigen 3D-Drucker des Unternehmens werden in verschiedenen Marktbereichen mit medizinischem, professionellem und industriellem Hintergrund eingesetzt und aufgrund ihrer Präzision, Oberflächenbeschaffenheit, Funktionalität und Geschwindigkeit geschätzt. Das geistige Eigentum von EnvisionTEC umfasst mehr als 140 anhängige und bereits erteilte Patente sowie 170 rechtlich geschützte Materialien.

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Trial Attorneys Laud Historic Judicial Approach That Led To $265 Million Settlement In Amtrak Fatal Derailment Case

PHILADELPHIA, July 31, 2017 /PRNewswire-USNewswire/ -- Trial attorneys Thomas R. Kline, Robert J.  Mongeluzzi and Benedict Morelli today reacted to today's landmark Memorandum of Judge Legrome D. Davis, Jr., USDC Eastern District of Pennsylvania, in the $265 Million settlement reached in the Amtrak Train No. 188 derailment Federal Multidistrict Litigation (MDL No. 2654). They each represented victims in the 2015 derailment and served on the Plaintiffs Management Committee (PMC) in the litigation that recently concluded with the distribution of proceeds.

The Memorandum of U.S. District Court Judge Davis states in part, "In sum, the Settlement Program was the most fair and reasonable option—presenting the greatest likelihood of a successful recovery for the greatest number of claimants." He noted that, "The Program created a Fund that provides the best possible recovery—that is, the present value of the maximum statutory limit of Amtrak's liability, $265 million, which has been equitably and expeditiously distributed to all claimants."  

Referring to the challenge of reaching a fair settlement amount given the statutory restraint of the Federal damages cap, the Judge wrote, "If Plaintiffs were successful at trial, it is fairly certain that they would be entitled to substantial compensatory damages awards, likely aggregating more than $500 million. However, it is equally apparent that the litigation risks inherent in pressing forward with separate trials could eliminate any monetary recovery for some, if not many claimants."

He added, "In sum, the Settlement Program was the most fair and reasonable option—presenting the greatest likelihood of a successful recovery for the greatest number of claimants. "

Thomas R. Kline (K&S), stated in reaction to the Memorandum, "Judge Davis describes an extraordinary achievement in MDL history, which will serve as the standard for the management of MDL and mass disaster litigation in the future by marshaling under his brilliant leadership all of the necessary components (including the tireless effort's by himself, and Masters William Manfredi and Diane Welsh) which resulted in a equitable distribution of a limited fund—obtaining the most justice possible for the many who were so terribly injured and families who lost love ones."

Robert J. Mongeluzzi (SMBB) said, "In addition to the extraordinary leadership of Judge Davis, The Plaintiffs Management Committer, led by Tom Kline and Chip Becker, steadfastly and resiliently forged a consensus among themselves and the plaintiffs bar, working with the Court to establish a structure for a fair and equitable resolution which could not have been accomplished without a large reservoir of experience and dedication to the cause of justice—all done for the common good with no common benefit compensation."  

And Mr. Morelli added, "The record speed and just resolution of this matter for those victims like my client, Chef Eli Kulp, is a remarkable achievement by the Court and the lawyers who worked tirelessly to reach this end. While there is no amount of money that can undo the physical and emotional harm the victims endured, these settlements will hopefully offer some degree of closure and justice."

View original content:http://www.prnewswire.com/news-releases/trial-attorneys-laud-historic-judicial-approach-that-led-to-265-million-settlement-in-amtrak-fatal-derailment-case-300496980.html

SOURCE Kline & Specter

The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective

SAN FRANCISCO–(BUSINESS WIRE)–The merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (Napo) became effective today, July 31, 2017, at which point Jaguar Animal Health’s name changed to Jaguar Health, Inc. (Jaguar) and Napo began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of Mytesi®, which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Although Jaguar’s name has changed, the public company will continue to trade under the same Nasdaq ticker symbol: JAGX.

The terms of the merger include additional funding for the combined company, at $0.925 per share as disclosed in the definitive joint proxy statement/prospectus. As of today’s date, the combined company has approximately 66 million shares outstanding, and approximately 98 million shares outstanding on a fully diluted basis.

“We are thrilled that the merger of Jaguar and Napo has become effective. It is truly transformational for Jaguar Health to forward-integrate into an important revenue stream from Mytesi®, for which we hold unencumbered global rights and are pursuing multiple follow-on indications for various chronic gastrointestinal disorders. We estimate the potential U.S. market for Mytesi® to be approximately $100 million in gross annual sales, and anticipate that Mytesi® will generate approximately $7.0 million in revenue by April 2018 for its current, FDA-approved specialty indication,” Lisa Conte, Jaguar’s president and CEO, stated.

Jaguar Health is pursuing a follow-on indication for Mytesi® in chemotherapy-induced diarrhea, an important supportive care indication for patients undergoing primary or adjuvant chemotherapy for cancer treatment. Mytesi® is in development for orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; as a second-generation anti-secretory agent for use in cholera patients; and for supportive care for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Mytesi® has demonstrated benefit to D-IBS patients in published Phase 2 studies.

Jaguar Health’s next expected veterinary product commercial launch will be for Equilevia, a personalized premium proprietary total gut health product for equine athletes, which will be non-prescription.

Available Audio Recording of Jaguar’s July 28, 2017 Conference Call

The Jaguar management team hosted a conference call on Friday, July 28, 2017 to discuss the merger. Interested individuals can access an audio recording of the call on the investor relations section of Jaguar’s website (click here) for 90 days following the call. A dial-in replay of the call is also available, through August 4, 2017, at 844-512-2921 (U.S. Toll Free) or 412-317-6671 (International). Participants must use the following code to access the dial-in replay of the call: 4112552.

About Mytesi®

Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Mytesi® is in development for multiple possible follow-on indications, including chemotherapy-induced diarrhea; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and as a second-generation anti-secretory agent for use in cholera patients. Canalevia is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. Equilevia is Jaguar’s non-prescription product for total gut health in equine athletes. Canalevia and Equilevia contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm Calf and Neonorm Foal are Jaguar’s lead non-prescription animal products. Mytesi®, Canalevia, Equilevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals.

For more information about Jaguar, please visit http://jaguar.health. For more information about Napo, please visit http://napopharma.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the benefits of the merger between Jaguar and Napo, Jaguar’s estimate that the potential U.S. market for Mytesi® is approximately $100 million in gross annual sales, Jaguar’s projection that Mytesi® will generate approximately $7.0 million in revenue by April 2018, possible follow-on indications for Mytesi®, and Jaguar’s expectation that its next veterinary product commercial launch will be for Equilevia. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Jaguar-JAGX

Glancy Prongay & Murray LLP Commences Investigation on Behalf of FireEye, Inc. Investors

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf investors of FireEye, Inc. (“FireEye” or the “Company”) (NASDAQ: FEYE) concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the FireEye investigation page on our website at www.glancylaw.com/case/fireeye-inc-0.

The investigation concerns whether FireEye and certain of its officers and/or directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 30, 2017, hackers leaked the personal and professional records of an analyst for the Company’s Mandiant subsidiary, stating “[t]his leak was just a glimpse of how deep we breached into Mandiant, we might publish more critical data in the future.”

On this news, FireEye’s stock price fell $0.65 per share, or 4.25%, on July 31, 2017, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased FireEye securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Rayonier Advanced Materials and Tembec Announce Termination of the Hart-Scott-Rodino Waiting Period

JACKSONVILLE, Fla. & MONTREAL–(BUSINESS WIRE)–Rayonier Advanced Materials Inc. (NYSE: RYAM) (“Rayonier Advanced Materials”) and Tembec Inc. (TSX: TMB) (“Tembec”) announced today that they received notification from the United States Department of Justice and the Federal Trade Commission that the Hart-Scott-Rodino premerger notification waiting period was terminated as of 3:32 p.m. ET on July 31, 2017 in connection with the previously announced proposed statutory arrangement under Section 192 of the Canada Business Corporations Act (the “Transaction”) involving the acquisition by Rayonier Advanced Materials of all of the outstanding shares of Tembec.

The Transaction has already received clearance from Germany’s Federal Cartel Office and applications for clearance from the applicable regulatory authorities in Canada and China, respectively, are pending. Subject to obtaining the approval of the Québec Superior Court, which is anticipated at a hearing scheduled for August 7, 2017, and other necessary approvals, as well as the satisfaction or waiver of the conditions to the Transaction, it is expected that the Transaction will be completed in the fourth quarter of 2017.

About Rayonier Advanced Materials

Rayonier Advanced Materials is a leading global supplier of high purity cellulose, a natural polymer commonly found in cell phones, computer screens, filters and pharmaceuticals. The company engineers dozens of customized products at its plants in Florida and Georgia, delivering unique properties, unparalleled consistency and exceptional quality. Rayonier Advanced Materials’ facilities can produce approximately 485,000 tons of high purity cellulose and 245,000 tons of commodity products. With approximately 1,200 employees and revenues of US$870 million Rayonier Advanced Materials is routinely ranked among the nation’s top 50 exporters, shipping products to five continents, 35 countries and 80 ports around the world. More information is available at www.rayonieram.com.

About Tembec

Tembec is a manufacturer of forest products – lumber, paper, pulp and high purity cellulose – and a global leader in sustainable forest management practices. Principal operations are in Canada and France. Tembec has approximately 3,000 employees and annual sales of approximately C$1.5 billion. Tembec is listed on the Toronto Stock Exchange (TMB). More information is available at www.tembec.com.

Forward-Looking Statements

This document contains statements that are forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to: the timing of the closing of the Transaction; whether the Transaction will be consummated at all and the ability to obtain required regulatory approvals and satisfy the other conditions to closing the Transaction; the expected benefits of the Transaction and whether such benefits will be achieved on a timely basis or at all; the ability of Tembec and Rayonier Advanced Materials to successfully integrate their respective businesses; prolonged weakness in general economic conditions; competitive pressures in the markets in which we operate; customer concentration; unfavorable weather conditions or natural disasters; reliance on government permits or approvals; risks related to federal, state, local and foreign government laws, rules and regulations; risks related to the reliance on information technology; manufacturing issues that may arise; adverse consequences of current or future legal claims; ability to hire and retain a sufficient seasonal workforce; labor relations with the unions representing Rayonier Advanced Materials’ hourly employees; changes in transportation-related costs and availability; risks related to workforce, including increased labor costs; the failure to attract and retain key personnel; the failure to innovate to maintain competitiveness, grow the business and protect intellectual property; fluctuations in foreign currency exchange rates; impairments or write downs of assets; changes in accounting estimates and judgments, accounting principles, policies or guidelines; the effect of current and future environmental laws and regulations as well as changes in circumstances on the cost and estimated future cost of required environmental expenditures; material adverse changes in financial condition; any failure by Rayonier Advanced Materials to realize expected benefits from its separation from Rayonier Inc.; financial obligations under agreements related to debt; and other risks detailed in Rayonier Advanced Materials’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” section of Rayonier Advanced Materials’ Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in Tembec’s filings with the Canadian Securities Administrators, including the “Risk Factors” section of Tembec’s Annual Information Form for the fiscal year ended September 24, 2016 and Tembec’s Third Quarter Report for the fiscal quarter ended June 24, 2017. All forward-looking statements attributable to Tembec or Rayonier Advanced Materials or any persons acting on their behalf are expressly qualified in their entirety by these cautionary statements. All forward-looking statements in this document are made as of the date hereof and neither Tembec nor Rayonier Advanced Materials undertakes any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as may be required by law.

Additional Information

Further information regarding the transaction is contained in the management information circular in connection with the special meeting of the Tembec shareholders filed by Tembec with the Canadian Securities Administrators on June 23, 2017 and furnished by Rayonier Advanced Materials on Form 8-K filed June 23, 2017 with the U.S. Securities and Exchange Commission, the material change report filed by Tembec with the Canadian Securities Administrators on July 24, 2017 and the Form 8-K filed by Rayonier Advanced Materials on July 24, 2017 with the U.S. Securities and Exchange Commission. Investors and security holders are urged to read the information circular, as it contains important information concerning the proposed transaction. Investors and security holders may obtain a copy of the arrangement agreement, information circular and other meeting materials at www.sec.gov and www.sedar.com. This document is for informational purposes only.